文献速递免疫规划传染病防控与疫情报告

南非HPV疫苗接种对青少年女孩HPV流行率的人群影响

Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study.
PubMed 文献 · Lancet Glob Health · 2026-01-01

HIV感染者中同样显著下降。

要点

  • 除HPV-31和HPV-45外,其他HPV型别未见显著下降。

核心结论

  • 南非两剂次HPV疫苗接种项目在高HIV负担环境下对青少年女孩HPV-16/18流行率产生显著人群影响。
  • HIV感染者中观察到与总体相似的疫苗影响。

研究设计与样本

  • 重复横断面研究,2019年调查估计接种前基线,2023年调查估计接种后流行率。
  • 共纳入2470名17-18岁女孩,接种前819名(248名HIV感染者),接种后1538名(295名HIV感染者)。
  • 样本来自自由州、豪登、普马兰加和西北四省15家初级卫生保健诊所,采用自采阴道样本检测HPV。
  • 接种状态通过地区登记和自报数据评估,采用广义线性回归估计调整患病率比。

主要发现

  • 除HPV-31和HPV-45外,其他HPV型别未见显著下降,符合交叉保护现象。

关键数值与推荐

  • 学校为基础的两剂次HPV-16/18疫苗接种项目2014年引入,面向四年级女孩(≥9岁)。
  • 至少接种一剂者覆盖率87%;主要结局为两出生队列间HPV流行率的相对下降。

临床怎么用

  • 支持在高HIV负担地区维持高覆盖率常规HPV疫苗接种以降低疫苗型HPV感染。
  • HIV感染青少年女孩同样可从HPV疫苗接种中获得显著保护。

局限性

  • 为重复横断面设计,接种状态依赖地区登记与自报数据,可能存在错分。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A school-based human papillomavirus (HPV) vaccination programme providing protection against types 16 and 18 of HPV was introduced in South Africa in 2014 for Grade 4 girls (aged ≥9 years), achieving 87% coverage among learners with at least one of the two recommended doses. We evaluated the programme's impact on HPV prevalence among adolescent girls in a setting of high HIV prevalence. METHODS: In this repeat cross-sectional study, girls aged 17-18 years were invited from 15 primary health-care clinics in four provinces (Free State, Gauteng, Mpumalanga, and North West) of South Africa to provide a self-collected vaginal sample for HPV testing (AnyPlex II HPV28, Seegene, Seoul, South Korea). A survey done from June 19 to Dec 11, 2019, estimated baseline (pre-vaccine) HPV prevalence. A repeat survey done from Feb 16 to Dec 6, 2023, estimated HPV prevalence in a group eligible for the vaccination programme (post-vaccine). Vaccination status was assessed through district registers and self-reported data. The primary outcome was the impact of the HPV vaccination programme, measured as the relative reduction in HPV prevalence between the two birth cohorts using generalised linear regression (estimating adjusted prevalence ratios), overall and by HIV status. FINDINGS: Of 2470 participants enrolled, 819 girls were recruited for the pre-vaccine survey (248 living with HIV) and 1538 for the post-vaccine survey (295 living with HIV). Prevalence of HPV vaccine types HPV-16 and HPV-18 declined by 83%, from 21·6% (177 of 819 participants) in the pre-vaccine group to 3·2% (49 of 1538 participants) in the post-vaccine group (adjusted prevalence ratio 0·17, 95% CI 0·12-0·24; p<0·0001). A similar reduction was observed among those living with HIV, with prevalence decreasing from 29·4% (73 of 248 participants) in the pre-vaccine group to 4·4% (13 of 295 participants) in the post-vaccine group (adjusted prevalence ratio 0·18, 95% CI 0·10-0·32; p<0·0001). No significant reductions were noted for other HPV types, except HPV-31 and HPV-45, which is consistent with cross-protection. INTERPRETATION: In this large-scale evaluation of South Africa's two-dose HPV vaccination programme, we observed impacts similar to those seen with three-dose programmes in high-income settings, including equivalent impacts among adolescent girls living with HIV. These findings underscore the substantial population-level benefits of high-coverage routine HPV vaccination in a high-HIV-burden setting. FUNDING: Australian National Health and Medical Research Council and the Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Machalek DA, Nyemba DC, Travill D, et al. Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study. Lancet Glob Health. 2026. PMID: 41856140. doi:10.1016/S2214-109X(25)00525-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。